The tumor suppressor gene, MMAC/PTEN, has phosphatase, C2, and PDZ-binding domains as well as potential sites of regulation by phosphorylation, including tyrosine phosphorylation, which may contribute to its ability to modulate cell growth and viability. Several obvious and signi®cant motifs were found in MMAC/ PTEN, including most notably, a catalytic domain of tyrosine phosphatase (IHCxxGxxRS/T) and several potential tyrosine phosphorylation sites. To examine the functional signi®cance of tyrosine phosphorylation of MMAC/PTEN, retroviral constructs were generated with mutations at two putative tyrosine phosphorylation sites (Y240A/Y240F and Y315A/Y315F). Stable expression of wild-type MMAC/PTEN in U251 human glioma cells (which do not normally produce a functional MMAC/PTEN gene product) resulted in a signi®cant reduction of tumor growth in nude mice, decreased growth rate, saturation density, and colony formation in vitro, as well as dephosphorylation of D3-phosphorylated phosphatidylinositols (PtdIns) in vitro. Mutation of Y240 or Y315 to either alanine or phenylalanine abrogated the ability of MMAC/PTEN to alter growth rate, saturation density, and colony formation in vitro. The ability of MMAC/PTEN to limit tumor growth in nude mice was markedly decreased but not abrogated by mutation of Y240 or Y315 to alanine. Thus, Y240 and Y315 are required for MMAC/PTEN to decrease tumor growth in vitro and in vivo. In contrast to wild-type MMAC/ PTEN, mutant MMAC/PTEN containing Y240A or Y315A was unable to dephosphorylate D3-phosphorylated PtdIns in vitro. Thus, Y240A and Y315A are involved in the ability of MMAC/PTEN to dephosphorylate PtdIns and regulate tumor cell growth in vitro and in vivo.
Introduction
The identi®cation and characterization of homozygous deletions of human chromosome band 10q23 in brain and breast cancers led to the cloning of a novel tumor suppressor gene designated ®rst as MMAC (Steck et al., 1997) or PTEN or TEP1 . Loss of MMAC/PTEN expression or mutations in the gene are frequent events in the molecular pathogenesis of several familial cancer predisposition syndromes Marsh et al., 1997) and sporadic tumors from several cell lineages, including glioblastomas, as well as cancers of prostate, uterus, bladder and malignant melanomas (Furnari et al., 1997; Besson et al., 1999) . Reintroduction of wild-type MMAC/PTEN suppresses in vitro and in vivo growth of glioblastoma cells de®cient in the functional gene product (Furnari et al., 1997; Davies et al., 1998 Davies et al., , 1999 Lu et al., 1999) , con®rming the tumor suppressor role of MMAC/ PTEN. In addition, the phenotype of MMAC/PTEN null mice supports the conclusion that MMAC/PTEN functions as a tumor suppressor (Stambolic et al., 1998; Di Cristofano et al., 1998; Podsypanina et al., 1999) .
MMAC/PTEN was initially demonstrated to be a dual speci®city protein phosphatase dephosphorylating serine, threonine, and tyrosine residues (Meyers et al., 1998) . Subsequent studies documented that the MMAC/PTEN protein dephosphorylated the D3 position of phosphatidylinositol 3,4,5 trisphosphate [PtdIns(3,4,5)P 3 ] and phosphatidylinositol (3,4) biphosphate [PtdIns(3,4)P 2 ] (Maehama and Dixon, 1998) , produced as a consequence of phosphatidylinositol 3-Kinase (PI3K) activity. As PI3K has been shown to be essential for cellular growth, survival, and multiple other functions, this provides a potential mechanism for the tumor suppressor function of MMAC/PTEN. D3-phosphorylated PtdIns bind to pleckstrin homology (PH) domains, thus recruiting to the membrane and activating a number of dierent intracellular proteins such as ILK and PDK1, which phosphorylate Akt/ PKB, as well as Akt/PKB itself (Franke et al., 1997; Stokoe et al., 1997) . Akt/PKB, in turn, has been shown to phosphorylate a number of substrates that are involved in cell survival, metabolism, and proliferation (Staal, 1987; Jimenez et al., 1998; Bellacosa et al., 1991; Chang et al., 1997) . Therefore, MMAC/PTEN may be a physiologic antagonist of signaling through the PI3K pathway and of subsequent physiologic events. MMAC/ PTEN has also been shown to interact with and dephosphorylate focal adhesion kinase (FAK), resulting in the inhibition of cell migration, integrin-mediated cell spreading, and formation of focal adhesions (Tamura et al., 1998 (Tamura et al., , 1999a . Thus, MMAC/PTEN may regulate a number of processes critical to normal and malignant cellular function.
Several structural motifs have been identi®ed that may contribute to the function of the MMAC/PTEN protein product. These include a phosphatase domain, several putative tyrosine and serine/threonine phosphorylation sites, a C2 domain (Lee and Sun, 1999) , and a PDZ-binding domain at the C-terminus , along with extensive homology with the cytoskeleton proteins tensin and auxillin within the amino terminus. These domains may regulate protein ± protein interactions, protein ± lipid interactions, protein stability, and phosphatase activity. Weng et al. (2001) have demonstrated that MMAC/PTEN blocks cell cycle progression dierentially through down-regulation of the positive cell cycle regulator, cyclin D1, by its protein phosphatase activity, and through up-regulation of the negative cell cycle regulator, p27, by its lipid phosphatase activity. Although several reports have elucidated the importance of the phosphatase domain for the tumor suppressor activity of MMAC/PTEN (Furnari et al., 1998) , the role of tyrosine phosphorylation sites has not yet been evaluated. In an attempt to examine the potential signi®cance of some of these motifs in growth regulation and signaling, we generated a series of retroviral MMAC/PTEN constructs with mutations aecting putative tyrosine phosphorylation sites, the phosphatase domain, and the PDZ-binding domain. These constructs were stably introduced into U251 glioma cells, which lack a functional MMAC/PTEN gene (Steck et al., 1997) . The cells were then assayed to determine the eects of these mutations on the biologic and biochemical functions of MMAC/PTEN.
Results

MMAC/PTEN inhibits cell growth in vitro and in vivo
To examine the functional signi®cance of putative regulatory domains in MMAC/PTEN, we stably expressed wild-type MMAC/PTEN and MMAC/ PTEN constructs with mutations in the phosphatase domain (C124S, R130G), tyrosine phosphorylation sites (Y240A/Y240F and Y315A/Y315F), and termination mutations in the PDZ-binding site (ter388 and ter398) in U251 glioblastoma cells (Figure 1a) . Levels of wild-type and mutant MMAC/PTEN expression were similar in each of the cell lines generated (Figure 1b, c) and were similar to the levels of endogenous MMAC/PTEN expressed in cell lines (not presented (Figure 3 ). In contrast, U251 cells expressing wild-type MMAC/ PTEN failed to form tumors in nude mice (Figure 3 ).
Y240 and Y315 are critical for growth regulation by MMAC/PTEN
To assess the role of tyrosine phosphorylation of MMAC/PTEN in its biochemical and cellular functions, we mutated two potential tyrosine phosphorylation sites in MMAC/PTEN to either alanine or phenylalanine (Y240A/Y240F and Y315A/Y315F, Figure 1a ). Mutations of tyrosine to a non-phosphorylatable alanine or phenylalanine residue has been utilized in multiple systems to explore the role of tyrosine phosphorylation in functional outcomes (Pluskota et al., 2000; Porter et al., 2000) . In our study, we found levels of expression of wild-type and mutant MMAC/PTEN constructs were similar (Figure 1b, c) . Src family kinases are overexpressed in multiple tumor lineages and also play a critical role in signal transduction from multiple growth factor receptors. When the eects of stimulation of Src kinases were mimicked by expression of activated Src family kinases, MMAC/PTEN became tyrosine phosphorylated ( Figure 1d ). Reduced tyrosine phosphorylation of MMAC/PTEN was observed when tyrosine 240 or 315 mutants were mutated to nonphosphorylated residues ( Figure 1e ).
The mutation of tyrosine residues to phenylalanine abrogated the ability of MMAC/PTEN to suppress colony formation (Figure 2a, b, Table 2a, b) , and to decrease growth rate and saturation density in vitro (Table 1a , b) suggesting that phosphorylation of these sites is important in the ability of MMAC/PTEN to regulate anchorage-dependent and -independent growth. The mutations of Y240A and Y315A markedly decreased the ability of MMAC/PTEN to inhibit tumor formation in vivo (Figure 3 ).
Mutation of Y240 or Y315 to alanine abrogates PtdIns phosphatase activity
MMAC/PTEN has been demonstrated to act as a D3-phosphotidylinositol phosphatase ± contributing to its tumor suppressor activity. This activity is re¯ected by the ability of MMAC/PTEN to dephosphorylate PtdIns in vitro (Maehama and Dixon, 1998) . Mutations in MMAC/PTEN, including mutations in the phosphatase domain (C124S and P130G) and at tyrosine phosphorylation sites (Y240A and Y315A), comprised its ability to dephosphorylate PtdIns (3,4)P 2 in membrane micelles (Figure 4 ). Similar results were observed when the constructs were assessed for the ability to dephosphorylate PtdIns (3,4,5)P 2 (data not presented). As indicated in Figure 4 , wild-type, ter388, and ter398 MMAC/PTEN dephosphorylate PtdIns (3,4)P 2 with relatively equal eciency.
An intact phosphatase domain is required for MMAC/PTEN to inhibit cell growth
To study the impact of the phosphatase domain of MMAC/PTEN on growth regulation, we introduced into MMAC/PTEN the naturally occurring C124S and (Figure 4 ).
Discussion
The present study was designed to examine the signi®cance of tyrosine phosphorylation sites and other structural motifs in the MMAC/PTEN protein with respect to growth suppression in vivo and in vitro and the ability to regulate PI3K-mediated signaling in U251 human glioma cells. (Morimoto et al., 1999) . A recent report has also demonstrated that the PDZbinding domain of MMAC/PTEN is not obligatory for growth regulation, but that larger truncations of the C2 domain at the C-terminus of MMAC/PTEN result in an unstable protein with decreased phosphatase activity . Vazquez et al. (2000) , however, demonstrated that the C-terminal domain of MMAC/PTEN is required for protein stability.
Although the PDZ-binding domain of MMAC/ PTEN may be dispensable for some functions, it may play a role in some other functions such as membrane ruing (Leslie et al., 2000) . Recently, the PDZ-binding domain of MMAC/PTEN has been demonstrated to interact with PDZ domains in MAGI 1, MAGI 2, and MAGI 3, novel members of a family of PDZ-domains containing membrane-associated guanylate kinases (MAGUKs) (Wu et al., 2000a,b) . The MMAC/ PTEN-MAGI 1 complexes appear to be localized at tight junctions in the membrane of epithelial cells. Overexpression of MAGI 2 and MAGI 3 enhances the ability of MMAC/PTEN to decrease Akt activity and to localize to the cell membrane (Wu et al., 2000a,b) . however, the ability of MAGI 2 or MAGI 3 to increase the ability of MMAC/PTEN to decrease AKT/PKB activity has only been reported in 293 cells and only detected when limiting amounts of MMAC/PTEN were transfected into cells (Wu et al., 2000a,b) . Indeed, when the amounts of MMAC/PTEN present in normal cells were introduced, MAGI 2 or MAGI 3 did not alter the actions of MMAC/PTEN (Wu et al., 2000a,b) . Thus, although the role of the PDZ-binding domain in speci®c functions of MMAC/PTEN remains unclear, it is dispensable for its eects on growth regulation and signaling in U251 cells. Phosphorylation and dephosphorylation of serine and threonine residues in MMAC/PTEN have been shown to regulate both MMAC/PTEN stability and activity (Vazquez et al., 2000; Torres and Pulido, 2001 ). The sequence MYFEF (which included amino acid Y240) is located within a consensus motif for binding to the SH2 domain-containing tyrosine phosphatase SHP1, suggesting that a phosphorylation-induced interaction between these two phosphatases may occur. Mutation of the Y240 or Y315 consensus tyrosine phosphorylation motifs either to alanine or phenylalanine in MMAC/PTEN abrogated the ability of MMAC/PTEN to decrease the growth rate of tumor cells in vitro under anchorage-dependent or -independent conditions. Further, they markedly decreased the ability of MMAC/PTEN to inhibit tumor growth in vivo. These eects were associated with an abrogation of the ability of MMAC/PTEN to dephosphorylate PtdIns in vitro.
Taken together the data indicate that the PDZbinding domain of MMAC/PTEN is dispensable for the function of MMAC/PTEN, at least as indicated by its ability to regulate cell growth in vitro and in vivo and also to dephosphorylate PtdIns. Furthermore, as indicated by others, mutations in the phosphatase domain of MMAC/PTEN have marked eects on the ability of MMAC/PTEN to regulate cell growth in vitro and in vivo and also to dephosphorylate PtdIns. Finally, intact tyrosines at amino acids 240 and 315 are critically important for the ability of MMAC/PTEN to regulate cell growth in vitro and in vivo and also to dephosphorylate PtdIns.
Materials and methods
Cells
The U251 human glioblastoma cell line (ATCC) was maintained in culture medium Dulbecco's modi®ed Eagle's medium [DMEM] F12, 5% fetal bovine serum (FBS) in a humidi®ed atmosphere containing 5% CO 2 at 378C. These cells were shown previously to have a mutated MMAC/ PTEN gene (723 ins TT) and failed to express a detectable protein product (Steck et al., 1997) .
Mutagenesis and retrovirus construction
PLNCX, a 6.2-kb retroviral vector (Clontech) derived from Moloney murine leukemia virus (MoMuLv), was utilized for retroviral gene delivery and expression. A full-length MMAC/PTEN retroviral construct (wild-type MMAC/ PTEN) was generated by ligating the Not1-Sal1 fragment ) and potential tyrosine phosphorylation sites (Y240A/Y240F and Y315A/Y315F), and termination mutations at the C-terminal PDZ-binding domain (ter388 and ter398) were generated in pBluescript-MMAC using the QuikChange TM Site-Directed Mutagenesis Kit (Stratagene) and the wild-type-MMAC/PTEN and mutant MMAC/PTEN constructs were then transferred to pLNCX. Sequences were con®rmed both in pBluescript and pLNCX using the USB reagent kit (Amersham Life Sciences) for DNA sequencing with Sequenase T 7 DNA polymerase and 7-deaza-dGTP.
Stable transfections
Retrovirus producer cells PT67 were grown in DMEM/F12 containing 10% FBS, 100 U/ml penicillin-streptomycin, and 2mM glutamine, and transfected with wild-type and mutant constructs of MMAC/PTEN by calcium phosphate precipitation. The human glioblastoma cell line U251 was infected with 48 h supernatants from the transfected PT67 cells. After 14 h of incubation, cells were maintained in DEME/F12 and colonies were selected using 400 mg/ml of G418. Isolated colonies were picked, expanded, and screened for the expression of MMAC/PTEN protein by immunoblotting.
Immunoblotting
For cytoplasmic cell lysates, cells were washed with ice-cold PBS and lysed by incubating on ice in a buer containing 50 mM HEPES, pH 7.0, 150 mM NaCl, 1 mM EGTA, 100 mM NaF, 10 mM Na 4 P 2 O 7 , 10% glycerol, 1% triton-X100, 1 mM Na 3 VO 4 , 1 mM pepstatin, 10 mg/ml aprotinin, 5 mM iodoacetic acid, and 2 mg/ml leupeptin. The lysates were clari®ed by centrifugation, and proteins in the supernatant were resolved by 7.5% SDS ± PAGE, electroblotted to PVDF membranes (Millipore), blocked in 5% skim milk in 16 TBS, 0.05% Tween-20, and probed with primary anti-MMAC/PTEN monoclonal antibody (Santa Cruz, CA, USA). Proteins were detected by chemiluminescence (ECL, Amersham, Chicago, IL, USA) following incubation with horseradish peroxidase-conjugated goat anti-rabbit or antimouse antibody.
Tyrosine phosphorylation of MMAC/PTEN
Cells were co-transfected with pCMV5 MMAC/PTEN and pCDNA3 Src/Lck plasmids as indicated using the Fugene transfected reagent kit (Boehringer Mannheim, Germany). After 30 h, cells were serum-starved for 12 h prior to cell lysis. Cell lysates prepared were used for immunoprecipitation with anti-MMAC/PTEN antibody (Santa Cruz, CA, USA). Immune complexes were precipitated with protein GSepharose beads (Amersham) and eluted by boiling in SDS sample buer. Eluted proteins were resolved by SDS ± PAGE and detected by Western blotting analysis with antiphosphotyrosine antibodies. Proteins were visualized by chemiluminescence following incubation with horseradish peroxidase-conjugated secondary antibodies.
Growth curves
Cells were seeded in triplicate in DMEM/F12 supplemented with 5% FBS at 1610 4 cells per well in 6-well plates. Cells were counted in triplicate on indicated days using a hemocytometer and doubling times were calculated. immunoprecipitates from Jurkat T cells were incubated with 20 mg PtdIns 4-monophosphate or PtdIns 4,5-bisphosphate for 30 min at room temperature in 20 mM Tris-HCl (pH 7.5), 75 mM NaCl, 10 mM MgCl 2 , 100 mM adenosine, 10 mM ATP, and [g-32 P]ATP (30 mCi). The reaction was terminated by the addition of 100 ml of 1 N HCl, and phospholipids were extracted with chloroform: methanol (1 : 1). MMAC/PTEN phosphatase assays were performed at 378C for 1 h in a buer containing 100 mM Tris-Cl (pH 8), 10 mM DTT, and 1 mM MgCl 2 , with [ 32 P]PtdIns(3,4)P 2 or [ 32 P]PtdIns(3,4,5)P 3 and immunoprecipitated MMAC/PTEN. The reaction was stopped by the addition of 100 ml of 1 NHCl. Lipids were extracted and resolved by thin layer chromatography (TLC) using Chloroform : Methanol : Acetone : Acetic Acid : distilled water in the ratio of 60 ml : 2 ml : 23 ml : 18 ml : 11 ml as described previously (Maehama and Dixon, 1998) .
Abbreviations MMAC/PTEN, mutated in multiple advanced cancers/phosphatase and tensin homologue; PI3K, phosphatydlinositol 3-Kinase; PtdIns, phosphatydlinositols; DMEM, Dulbecco's modi®ed Eagle's medium.
